Etanercept treatment in corticosteroid-dependent myasthenia gravis

ROWIN J., MERIGGIOLI M., Tuzun E., LEURGANS S., CHRISTADOSS P.

NEUROLOGY, vol.63, no.12, pp.2390-2392, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 63 Issue: 12
  • Publication Date: 2004
  • Doi Number: 10.1212/01.wnl.0000147242.92691.71
  • Journal Name: NEUROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2390-2392
  • Istanbul University Affiliated: Yes

Abstract

The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.